In an interview on CNBC, Moderna (MRNA +11.0%)
Chairman Noubar Afeyan said that Phase 2 studies evaluating its
COVID-19 vaccine candidate should launch this spring or early summer.
Approval for widespread deployment is still 12 – 18 months away,
however (emergency use authorization is a certainty if the vaccine is
shown to be safe and shows a protective effect, even if preliminary).
https://seekingalpha.com/news/3557971-moderna-up-11-on-encouraging-study-timeline-for-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.